AN2 THERAPEUTICS INC (ANTX) Stock News

USA - Nasdaq - NASDAQ:ANTX - US0373261058 - Common Stock

1.065 USD

-0.01 (-0.47%)

Last: 12/4/2025, 8:04:21 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ANTX Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

25 days ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

a month ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

2 months ago - By: Benzinga - Mentions: SNGX CHEK ADAP AYTU ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a year ago - By: Benzinga - Mentions: CIA RPHM

Citizens And 2 Other Penny Stocks Insiders Are Buying

a year ago - By: InvestorPlace

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024

4 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

4 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

5 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

5 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

a year ago - By: BusinessInsider

News Image

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024

6 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

7 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

7 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

a year ago - By: InvestorPlace

Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?

2 years ago - By: BusinessInsider

News Image

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024

2 years ago - By: InvestorPlace

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024

7 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

8 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

9 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

9 months ago - By: AN2 Therapeutics, Inc.

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

10 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Participate at Upcoming Investor Conferences

10 months ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Participate at Upcoming Investor Conferences

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

a year ago - By: InvestorPlace - Mentions: AVD BBLG BW CMND ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

2 years ago - By: AN2 Therapeutics, Inc.

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights